Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in overall survival compared with biological therapy (moderate certainty).
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemmotherapy combined with biological therapy showed no clear difference in overall survival compared with chemotherapy (moderate certainty).
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Overall survival · advanced pancreatic cancer
Anti‐cancer therapy showed no clear difference in overall survival compared with best supportive care (moderate certainty).
1 finding from 1 review
Overall survival · advanced pancreatic cancer
Fluoropyrimidine combinations showed no clear difference in overall survival compared with fluoropyrimidine alone (low certainty).
1 finding from 1 review
Overall survival · palliative participants with esophageal and GE‐junction carcinoma
Summary of findings table: chemotherapy or targeted therapy agent(s)… leads to lower overall survival compared with control intervention alone (high certainty).
1 finding from 1 review
Overall survival · palliative participants with esophageal and GE‐junction carcinoma
Summary of findings table (subcomparison 1): chemotherapy or… leads to lower overall survival compared with BSC (high certainty).
1 finding from 1 review
Overall survival · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy
Summary of findings table (subcomparison 2): second‐line… probably leads to lower overall survival compared with control intervention alone (moderate certainty).
1 finding from 1 review
Overall survival · palliative participants with esophageal and GE‐junction carcinoma
Summary of findings table (subcomparison 3): chemotherapy agent(s)… probably leads to lower overall survival compared with control intervention alone (moderate certainty).
1 finding from 1 review
Overall survival · palliative participants with esophageal and GE‐junction carcinoma
Summary of findings table (subcomparison 4): targeted therapy agent… leads to lower overall survival compared with control intervention alone (high certainty).
1 finding from 1 review
Overall survival · palliative participants with AC of the esophagus
Summary of findings table (subcomparison 5): chemotherapy or… leads to lower overall survival compared with control intervention alone (high certainty).
1 finding from 1 review
Overall survival · palliative participants with SCC of the esophagus
Summary of findings table (subcomparison 6): chemotherapy or… leads to lower overall survival compared with control intervention alone (high certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations may leads to lower overall survival compared with 5‐FU/anthracycline combinations (without cisplatin) (low certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Irinotecan probably leads to lower overall survival compared with non‐irinotecan‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Docetaxel leads to lower overall survival compared with non‐docetaxel‐containing regimens (high certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Combination probably leads to lower overall survival compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Capecitabine showed no clear difference in overall Survival compared with 5‐FU‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Oxaliplatin may leads to lower overall Survival compared with the same regimen including cisplatin (low certainty).
1 finding from 1 review